Premier Business Partner

M&R Flag Cars

Check out our latest Edition!

 

alan blog tli

newswirelogo

  • Novartis to acquire Endocyte for $24 per fully diluted share in cash

  • LONDON, 18 Oct. 2018 (GLOBE NEWSWIRE) -- This is the Start of Day Message for GlobeNewswire.

  • As Disrupters Enter the Market and Vie for Position, Incumbents Must Deepen Their Customer Understanding, Foster Trust and Loyalty, and Improve Cross-Selling to Maintain Momentum, Says New Report by BCG

  • WAYNE, Pa., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet patient needs in aesthetic and medical dermatology and immunology, today announced the pricing of its underwritten public offering of 8,645,000 shares of its common stock at a price to the public of $10.75 per share.  In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,296,750 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $92.9 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about October 22, 2018, subject to customary closing conditions.  

Contact Us

Transportation and Logistics International

150 N. Michigan Ave., Suite 900
Chicago, IL 60601
312.676.1100  312.676.1101

Click here for a full list of contacts.

Latest Edition

Spread The Love

Back To Top